Published in J Bone Miner Res on March 14, 2005
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract (2006) 1.46
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int (2011) 1.45
Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. Calcif Tissue Int (2012) 1.41
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int (2007) 1.21
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int (2013) 1.05
Use of osteoporosis medications in older nursing facility residents. J Am Med Dir Assoc (2007) 1.00
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol (2008) 0.97
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int (2011) 0.95
Treatment and prevention of osteoporosis. Wien Med Wochenschr (2007) 0.93
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging (2006) 0.93
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (2012) 0.91
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int (2011) 0.91
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int (2012) 0.90
Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf (2010) 0.88
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. Calcif Tissue Int (2009) 0.88
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int (2013) 0.88
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med (2011) 0.87
Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females. Osteoporos Int (2014) 0.85
Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med (2010) 0.84
Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag (2006) 0.83
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. J Bone Miner Metab (2009) 0.82
Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis (2007) 0.81
Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther (2010) 0.80
Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporos Int (2009) 0.80
Efficacy of ibandronate: a long term confirmation. Clin Cases Miner Bone Metab (2010) 0.79
Patients with cirrhosis and ascites have false values of bone density: implications for the diagnosis of osteoporosis. Osteoporos Int (2011) 0.78
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging (2008) 0.78
Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clin Interv Aging (2006) 0.78
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. J Bone Miner Metab (2012) 0.78
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging (2008) 0.77
Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag (2006) 0.77
Once-monthly risedronate for postmenopausal osteoporosis. Int J Womens Health (2010) 0.76
Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review. Ther Adv Musculoskelet Dis (2011) 0.76
Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis. Medicine (Baltimore) (2015) 0.76
Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health (2014) 0.76
Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis. PLoS One (2016) 0.75
Clodronate: new directions of use. Clin Cases Miner Bone Metab (2015) 0.75
Surgical protocol in patients at risk for bisphosphonate osteonecrosis of the jaws: clinical use of serum telopetide CTX in preventive monitoring of surgical risk. Ann Stomatol (Roma) (2012) 0.75
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits. Rheumatol Int (2011) 0.75
[DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?]. Z Rheumatol (2006) 0.75
Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study. J Bone Miner Metab (2015) 0.75
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Effect of in utero and early-life conditions on adult health and disease. N Engl J Med (2008) 14.46
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr (2007) 9.61
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med (2006) 7.45
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 5.93
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Osteoporosis. Lancet (2006) 5.40
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab (2005) 5.31
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis (2004) 4.31
Using natural experiments to evaluate population health interventions: new Medical Research Council guidance. J Epidemiol Community Health (2012) 4.26
Cohort profile: The Southampton Women's Survey. Int J Epidemiol (2005) 4.11
Genome-wide association study identifies five loci associated with lung function. Nat Genet (2009) 4.10
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Official positions of the International Society for Clinical Densitometry. J Clin Densitom (2004) 3.63
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol (2006) 3.36
Grip strength, body composition, and mortality. Int J Epidemiol (2006) 3.36
Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res (2008) 3.33
Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res (2007) 3.31
A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing (2011) 3.27
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity. Hum Mol Genet (2008) 3.24
Prevalence and impact of musculoskeletal disorders of the upper limb in the general population. Arthritis Rheum (2004) 3.24
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Epigenetic gene promoter methylation at birth is associated with child's later adiposity. Diabetes (2011) 3.18
Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 3.11
Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem (2006) 3.10
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Objective measures of physical capability and subsequent health: a systematic review. Age Ageing (2010) 2.78
The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2007) 2.75
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med (2013) 2.73
Intelligence in childhood and chronic widespread pain in middle age: the National Child Development Survey. Pain (2012) 2.71
Relationship of obesity with osteoporosis. J Clin Endocrinol Metab (2007) 2.71
Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab (2002) 2.69
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum (2002) 2.66
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet (2008) 2.65
Does sarcopenia originate in early life? Findings from the Hertfordshire cohort study. J Gerontol A Biol Sci Med Sci (2004) 2.64
Epidemiology of hip fracture: Worldwide geographic variation. Indian J Orthop (2011) 2.60
Women's compliance with nutrition and lifestyle recommendations before pregnancy: general population cohort study. BMJ (2009) 2.54
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res (2015) 2.52
Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47
Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom (2005) 2.44
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab (2008) 2.43
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Vitamin D: some perspective please. BMJ (2012) 2.35
Developmental origins of midlife physical performance: evidence from a British birth cohort. Am J Epidemiol (2006) 2.35
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Osteoporosis: impact on health and economics. Nat Rev Rheumatol (2010) 2.25
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24